Saghmos Therapeutics Receives the US Patent for ST-62516 to Reduce the Risk of Acute Kidney Injury
Shots:
- The USPTO has issued patent no. 11,986,473 to the company’s ST-62516 under the title, ‘Prevention and/or Treatment of Contrast-Induced Acute Kidney Injury’, providing it exclusivity till 2037
- ST-62516 (trimetazidine) is now the holder of two US patents and one Japanese patent for reducing the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) post percutaneous coronary intervention (PCI)
- Furthermore, the company is planning to advance ST-62516 into P-III study for which it has partnered with the Duke Clinical Research Institute (DCRI) to plan the aspects and operationalization of the trial
Ref: Businesswire | Image: Saghmos Therapeutics
Related News:- IDEXX Launches First Veterinary Diagnostic IDEXX Cystatin B Test to Detect Kidney Injury in Cats and Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
